Quick Answer
Allergic disease is the most common chronic health condition affecting children in the United States. Approximately 8% of children have food allergy, 7.1% have hay fever, 10.7% have eczema, and 8.3% have asthma — with many children having more than one condition. All pediatric allergy categories have risen in prevalence since the 1980s. The atopic march — eczema → food allergy → rhinitis → asthma — describes the typical progression of sensitization.
Key Statistics at a Glance
Childhood Allergy Prevalence by Condition (US)
| Condition | Prevalence (Children) | Est. Children Affected (US) | Trend |
|---|---|---|---|
| Food allergy | ~8.0% | ~6 million | Rising ↑ |
| Atopic dermatitis (eczema) | ~10.7% | ~7.9 million | Rising ↑ |
| Allergic rhinitis (hay fever) | ~7.1% | ~5.2 million | Stable/rising ↑ |
| Asthma (all types) | ~8.3% | ~6.1 million | Stable/slight decline in recent years |
| Allergic asthma (subset) | ~60% of asthma cases | ~3.7 million | Parallel with overall asthma |
| Skin allergy (any type) | ~12.2% | ~9 million | Rising ↑ |
| Insect venom allergy | ~3% (sting reactions) | [Source: population-based estimate needed] | Unclear |
The Atopic March: Sequential Sensitization Data
The atopic march concept — originally described by Björkstén and confirmed in multiple longitudinal birth cohort studies including the German GINI Study, UK ALSPAC cohort, and US LEAP trial populations — describes how early-life eczema creates a sensitization pathway that predicts later food allergy, rhinitis, and asthma development. Key quantitative data on atopic march transitions:
| Transition | Proportion Progressing | Notes |
|---|---|---|
| Eczema → Food allergy | ~35–40% of children with eczema | Higher with earlier onset, more severe eczema |
| Eczema → Allergic rhinitis | ~30–50% over childhood | Risk increases with allergen sensitization breadth |
| Eczema → Asthma | ~20–30% | Filaggrin mutations predict higher transition risk |
| Food allergy → Asthma | Elevated 2–4× vs general population | [Source: meta-analysis data — verify with Annals AACI publications] |
| Rhinitis → Asthma | ~10–40% of rhinitis patients | Depends on allergen profile and geographic region |
Demographic and Racial/Ethnic Patterns
Childhood allergy burden is not evenly distributed across demographic groups. CDC NHIS data consistently shows that Black American children have higher rates of diagnosed asthma (~14%) compared to white (~7%) and Hispanic (~8%) children. Food allergy diagnoses are higher in non-Hispanic white children in some datasets, though this may partially reflect healthcare access differentials in diagnosis rates. Eczema is more common and more severe in children of color in multiple US and UK studies.
Socioeconomic status is a cross-cutting factor: families with lower income have higher rates of allergic disease (particularly asthma) but lower rates of specialist access, prescribed epinephrine, and allergen immunotherapy utilization. These disparities are an active focus of allergy equity research. For pediatric-specific clinical guidance, see our pediatric allergies hub.
What the Data Means
The childhood allergy data presents a compelling public health argument for earlier, more systematic allergy screening and prevention. The LEAP trial (Learning Early About Peanut allergy) demonstrated that early introduction of peanut to high-risk infants (those with eczema or egg allergy) reduced peanut allergy development by ~80% — a landmark finding that has since been incorporated into AAP and AAAAI clinical guidelines. This represents the first evidence-based preventive intervention with demonstrated population-level impact potential.
The data also supports investment in equitable access to specialist allergy care. Children with uncontrolled allergic rhinitis perform worse academically, have more school absences, and have higher rates of behavioral difficulties — suggesting that early allergy management has benefits extending well beyond symptom control. See our main statistics hub and research center for ongoing study findings.
Data Sources & Methodology Note
Primary sources: CDC National Health Interview Survey (NHIS) 2021 child allergy module; Rona RJ et al. (global food allergy trends); FARE 2023 food allergy statistics; Du Toit G et al., NEJM 2015 (LEAP trial); Spergel JM, Current Opinion in Allergy 2010 (atopic march); ISAAC Phase III global eczema/asthma data. Transition probabilities between atopic march conditions are approximate and vary significantly across cohort studies and geographic populations. Racial/ethnic disparities data drawn from CDC/NHIS analyses.